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Abstract
Background
Previous studies have shown that smoking and smoking cessation may be associated with
health-related quality of life (HRQoL). In this study, we compared changes in HRQoL in peo-
ple who maintained abstinence with people who had relapsed to smoking.
Methods
This was a secondary analysis of data from a trial of a relapse prevention intervention in
1,407 short-term quitters. The European Quality of Life -5 Dimensions (EQ-5D) measured
HRQoL at baseline, 3 and 12 months. Smoking outcome was continuous abstinence from 2
to 12 months, and 7-day smoking at 3 and 12 months. We used nonparametric test for differ-
ences in EQ-5D utility scores, and chi-square test for dichotomised response to each of the
five EQ-5D dimensions. Multivariable regression analyses were conducted to evaluate
associations between smoking relapse and HRQoL or anxiety/depression problems.
Results
The mean EQ-5D tariff score was 0.8252 at baseline. People who maintained abstinence
experienced a statistically non-significant increase in the EQ-5D score (mean change
0.0015, P = 0.88), while returning to smoking was associated with a statistically significant
decrease in the EQ-5D score (mean change -0.0270, P = 0.004). After adjusting for multiple
baseline characteristics, the utility change during baseline and 12 months was statistically
significantly associated with continuous abstinence, with a difference of 0.0288 (95% CI:
0.0006 to 0.0571, P = 0.045) between relapsers and continuous quitters. The only difference
in quality of life dimensions between those who relapsed and those who maintained absti-
nence was in the proportion of participants with anxiety/depression problems at 12 months
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(30% vs. 22%, P = 0.001). Smoking relapse was associated with a simultaneous increase in
anxiety/depression problems.
Conclusions
People who achieve short-term smoking abstinence but subsequently relapse to smoking
have a reduced quality of life, which appears mostly due to worsening of symptoms of anxi-
ety and depression. Further research is required to more fully understand the relationship
between smoking and health-related quality of life, and to develop cessation interventions
by taking into account the impact of anxiety or depression on smoking.
Background
Cigarette smoking remains the leading preventable cause of premature deaths globally [1].
Results of previous studies have indicated that smoking is negatively associated with quality of
life [2, 3], and smoking cessation is associated with reduced depression and anxiety, and
improved quality of life [4, 5]. A study found that the level of happiness in ex-smokers who
stopped smoking for at least a year was similar to never smokers, and higher than current
smokers [6]. However, it is uncertain whether trying and failing to quit increases the level of
psychological distress and depression [7–10]. Some studies have reported a significant associa-
tion between smoking relapse and mental health problems [11, 12], while another study found
no greater tendency to relapse for quitters with worsened mental health [13]. Studies showing
that relapse is associated with simultaneous changes in quality of life or mood cannot identify
the causal direction between them, and these effects may work in both directions.
In a randomised controlled trial, we evaluated the effectiveness of different self-help book-
lets for preventing smoking relapse in people who had stopped smoking for four weeks, and
found no differences between trial arms in smoking relapse at 12 months [14, 15]. Here we
compared changes in health-related quality of life (HRQoL) in people who maintained absti-
nence with people who had relapsed to smoking. We also investigated whether anxiety or
depression problems were associated with subsequent smoking relapse, or smoking relapse
was associated with subsequent anxiety or depression problems.
Methods
This is a secondary analysis of data from a randomised trial (ISRCTN36980856) for smoking
relapse prevention [14, 15]. The study was approved for research ethics (UK National Research
Ethics Service REC reference: 11/EE/0091, dated 20/04/2011), and all participants were pro-
vided detailed information about the study and signed the consent form before participating.
Participants were recruited between August 2011 and June 2013, and the follow-up of partici-
pants was completed by July 2014. Note that the recruitment start date shown in the ISRCTN
registry (01/06/2011) was incorrect, and we confirm that the participant recruitment actually
started since August 2011 after the trial’s registration on 25/07/2011. The authors also confirm
that all ongoing and related trials for this intervention are registered. The study included 1,407
carbon monoxide (CO) verified quitters at 4 weeks after quit dates in stop smoking clinics.
The study excluded quitters who were pregnant, unable to read booklets in English, or younger
than 18 years. Participants received either a set of educational booklets or a single leaflet to pre-
vent smoking relapse, and were followed up at 3 and 12 months after the quit date. There was
Smoking relapse and quality of life
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no difference between trial arms in the occurrence of the primary endpoint in the trial, pro-
longed abstinence from 4 to 12 months (assessed by self-report of no more than five cigarettes
in total, and confirmed by CO<10ppm at the 12 month follow-up). In the current study, we
used usual continuous abstinence as the smoking outcome, defined similarly to the primary
endpoint but from baseline (1 month after the quit date) to the 12 month follow-up. In addi-
tion, we also collected data on 7-day self-report smoking at 3 months and 12 months post quit
date.
The European Quality of Life -5 Dimensions- 3 Level (EQ-5D) instrument was used to esti-
mate levels of HRQoL [16]. Participants were asked to complete the EQ-5D questions at base-
line (1 month after the quit date), and at 3 and 12 months after the quit date. EQ-5D
instrument has 5 dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/
depression. For each dimension, there are three possible responses: “no problems”, “some or
moderate problems”, and “severe or extreme problems”. In the current study, EQ-5D data
were analysed using two methods; utility scores based on EQ-5D and dichotomisation of
responses to each of the five EQ-5D dimensions.
Responses to EQ-5D dimensions were converted into a utility score (a scale where death is
equal to 0 and full health 1) using the York A1 tariff [17,18]. The York A1 tariff enables a value
to be assigned to each EQ-5D health state, where these scores are based on the preferences of a
large sample of the UK population. Because the EQ-5D scores are not normally distributed,
differences in EQ-5D scores between groups were tested using nonparametric Mann-Whitney
test (two sample Wilcoxon rank-sum test). For ordered groups, we used the nonparametric
test for trend (an extension of the Wilcoxon rank-sum test) [19]. We also calculated changes in
utility score for individual participants between baseline and 3 or 12 months. Although the dis-
tribution of EQ-5D original scores was asymmetric, data on changes in utility score from base-
line to the follow-up time point was symmetrically distributed. A previous study compared
different methods and found that ordinary least squares (OLS) regression model was accept-
able for the analysis of EQ-5D tariff data [2]. Therefore, as the main analysis, we performed
OLS linear regression analyses to estimate the relationship between the change in utility score,
as outcome, and smoking status as explanatory variable, after adjusting for multiple baseline
variables. The baseline variables adjusted in the analyses were age, gender, married or living
with a partner, unemployed or not, low level of education, free prescription, and the first ciga-
rette within 5 minutes after waking before quitting.
The participants included in the current study were relatively healthy, with a low propor-
tion of “severe or extreme problems” for individual EQ-5D dimensions. Therefore, responses
to each of the EQ-5D dimensions were dichotomised into two categories: “no problems” and
“some or severe problems” by combining “some to moderate problems” and “severe or
extreme problems” [2]. We used chi-square test to analyse the association between the smok-
ing outcome and problems in each of the five EQ-5D dimensions. Because differences in
HRQoL scores were attributable mainly to problems in the anxiety/depression dimension, we
explored the association between changes in smoking status and changes in anxiety/depression
problems.
Stata/IC version 13.1 was used for statistical analyses, and statistical significance was
defined as two sided P<0.05.
Results
The main characteristics of study participants are shown in Table 1. The mean age of the par-
ticipants was 47.8 years (SD 13.8). Of the 1,407 participants, 52.7% were females, 61.6% mar-
ried or living with a partner, 52.6% in paid employment, 32.1% with A level or above
Smoking relapse and quality of life
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Table 1. The main characteristics of study participants.
Baseline variables % (N = 1407) Baseline EQ-5D utility score: mean (SD) P value
Total 100% 0.8252 (0.2594)
Age (years):
Up to 39 29.5% 0.9042 (0.1823) Ptrend<0.001
40–59 45.8% 0.8028 (0.2817)
60 & above 24.7% 0.7701 (0.2739)
Sex:
Female 52.7% 0.8153 (0.2681) Pm-w = 0.084
Male 47.3% 0.8362 (0.2490)
Marital status:
Married/living with partner 61.6% 0.8390 (0.2524) Reference
Separated/divorced 15.9% 0.7742 (0.2922) Pm-w<0.001
Single 18.2% 0.8422 (0.2361) Pm-w = 0.876
Other/unknown 4.3% 0.7426 (0.2906) Pm-w<0.001
Ethnic origin:
White 98.4% 0.8248 (0.2602) Pm-w = 0.472
All other 3.6% 0.8485 (0.2080)
Employment status:
In paid employment 52.6% 0.9025 (0.1692) Reference
Unemployed 10.0% 0.7132 (0.3007) Pm-w<0.001
Looking after the home 7.4% 0.8229 (0.2685) Pm-w = 0.002
Retired 20.3% 0.7515 (0.2861) Pm-w<0.001
Full time student 1.2% 0.8918 (0.1720) Pm-w = 0.780
Other 8.5% 0.6480 (0.3890) Pm-w<0.001
Education:
Degree or equivalent 15.2% 0.8610 (0.2172) Ptrend<0.001
A level or equivalent 16.9% 0.8374 (0.2570)
GCSE or equivalent 34.1% 0.8477 (0.2425) (excluded
Other 12.4% 0.7924 (0.2926) “unknown”)
None 20.0% 0.7627 (0.2877)
Unknown 1.3% 0.8414 (0.2458)
Free prescription�:
Yes 56.3% 0.7702 (0.2947) Pm-w<0.001
No 43.7% 0.8989 (0.1791)
Cigarettes�20/day before quitting
Yes 55.5% 0.8086 (0.2750) Pm-w = 0.020
No 44.5% 0.8457 (0.2371)
First cigarette after waking up:
In 5 minutes 42.2% 0.7848 (0.2924) Ptrend<0.001
6–30 minutes 42.6% 0.8496 (0.2384)
>30 minutes 15.2% 0.8678 (0.1987)
Previous quit attempts:
None 11.1% 0.8622 (0.2289) Ptrend = 0.04
1 attempt 26.2% 0.8234 (0.2528)
2 attempts 23.7% 0.8327 (0.2718)
3 or more 39.0% 0.8123 (0.2633)
Longest quit time before:
Not applicable 11.2% 0.8622 (0.2289) Ptrend = 0.008
(Continued)
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education, and 56.3% in receipt of free prescription (free prescription is defined in Table 1). In
terms of smoking history, 55.5% of the participants smoked 20 or more cigarettes daily and
42.2% smoked the first cigarette after waking up before the current quit attempt. Of the partici-
pants, 88.9% had previously attempted to quit and 71.6% had managed to stop smoking for
more than 4 weeks before. The proportion of participants living with a smoking partner was
18.3%.
The number of people who completed the EQ-5D-3L questionnaire was 1348 (95.8%) at
baseline, 1290 (91.7%) at the 3 month follow-up and 1171 (83.2%) at the 12 month follow-up.
The mean EQ-5D tariff score was 0.8252 at baseline. In bi-variable analyses, EQ-5D scores at
baseline were statistically significantly associated with age, divorced or separated, employment
status, education level, in receipt of free prescription, heavy smokers before quitting, and pre-
vious quit history (Table 1). Results of multivariable regression analysis found that EQ-5D
scores at baseline were independently and negatively associated with age (P<0.001), being
female (P = 0.002), unemployment (P<0.001), and first cigarette within 5 minutes of waking
(P<0.001), after adjusting for other baseline characteristics.
After excluding three participants who died before the 12 month follow up, the proportion
of continuous abstinence from baseline to 12 months was 32.4%. The mean EQ-5D utility
scores at baseline, the 3 and 12 month follow up by smoking outcome are shown in Table 2.
The differences in EQ-5D utility score between relapsers and continuous quitters were statisti-
cally non-significant at baseline and 3 months, but were statistically significant at 12 months
(P = 0.040). The mean change in EQ-5D utility score between baseline and 12 months was
-0.0270 (significantly deteriorated, P = 0.004) for relapsers and 0.0015 (non-significantly
Table 1. (Continued)
Baseline variables % (N = 1407) Baseline EQ-5D utility score: mean (SD) P value
<1 week 6.3% 0.8311 (0.2634)
1–4 weeks 10.9% 0.8496 (0.2506)
>4 weeks, <6 months 33.1% 0.8210 (0.2656)
> = 6 months 38.5% 0.8115 (0.2631)
Living with a smoking partner:
Yes 18.3% 0.8327 (0.2530) Pm-w = 0.656
No 81.7% 0.8235 (0.2609)
Ptrend−the nonparametric test for trend across ordered groups (an extension of the Wilcoxon rank-sum test. Pm-w−Mann-Whitney test (two sample Wilcoxon rank-sum
test).
� Free prescription—The charge for a single prescription is £8.05 in the UK. Some people are entitled to free prescriptions because of their age (60 or over, or under 16,
or aged 16 to 18 in full-education), income (on Income Support or qualified via other benefits or tax credits), or medical condition. GCSE–The General Certificate of
Secondary Education.
https://doi.org/10.1371/journal.pone.0205992.t001
Table 2. Mean EQ-5D utility scores at baseline and follow-ups by smoking status.
Time point All participant Abstinent at 12 months Relapsed at 12 months P value
N Mean n Mean n Mean
Mean utility scores at different time points
Baseline 1348 0.8252 442 0.8289 903 0.8234 0.412
At 3 months 1290 0.8255 451 0.8247 836 0.8261 0.873
At 12 months 1171 0.8072 451 0.8307 720 0.7924 0.040
Two sample Wilcoxon rank-sum (Mann-Whitney) test was used for the test of mean utility scores at different time points, and t-test for the change in utility scores.
https://doi.org/10.1371/journal.pone.0205992.t002
Smoking relapse and quality of life
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improved, P = 0.883) for continuous quitters. After adjusting for multiple baseline characteris-
tics, the utility change during baseline and 12 months was statistically significantly associated
with continuous abstinence, with a difference of 0.0288 (95% CI: 0.0006 to 0.0571, P = 0.045)
between relapsers and continuous quitters.
For specific EQ-5D dimensions, smoking status at 12 months was not statistically signifi-
cantly associated with problems in mobility, self-care, usual activity, and pain or discomfort at
baseline and the follow-ups (Fig 1). Of the five EQ-5D dimensions, only problems in anxiety/
depression at 12 months was statistically significantly associated with smoking relapse (30%
for relapses vs. 22% for continuous quitters, P = 0.001).
The relationships between smoking reported at the two follow-ups and some/severe prob-
lems in anxiety or depression dimension are shown in Table 3. Anxiety/depression problems
at baseline were not significantly associated with smoking relapse at 3 months (P = 0.112) or at
Fig 1. Proportion of participants with some/severe problems in different EQ-5D dimensions by continuous
abstinence. In each EQ-5D dimension the “some problems” and “severe problems” were combined as “some/severe
problems”. Differences in “some/severe problems” between the relapse and abstinent was statistically significant only
for anxiety/depression dimension at 12 months (P = 0.001).
https://doi.org/10.1371/journal.pone.0205992.g001
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12 months (P = 0.841), and anxiety/depression problems at 3 months were not significantly
associated with smoking relapse at 12 months (P = 0.354). Smoking relapse at 3 months was
not statistically significantly associated with anxiety/depression problems at 12 months (OR
1.22, 95% CI 0.87 to 1.71; P = 0.246). However, smoking relapse at 3 or 12 months was statisti-
cally associated with anxiety/depression problems at the same time points (Table 3).
Fig 2 shows the proportion of participants with anxiety/depression problems by further
subgrouping smoking status at baseline, 3 and 12 months. The proportion of anxiety/depres-
sion problems among participants who remained abstinent at both 3 and 12 months was 27%
at baseline, and somewhat reduced to 22% at 3 months and 23% at 12 months. For participants
who did not smoke at 3 months but smoked at 12 months, the proportion of anxiety/depres-
sion problems was higher at 12 months (31%), compared with that at baseline (27%) and 3
months (23%). It is interesting to note the fluctuation of anxiety/depression problems among
participants who smoked at 3 months and did not smoke at 12 months; the proportion of anxi-
ety/depression problems was somewhat high at baseline (32%), considerably increased at 3
months (45%), and then much reduced at 12 months (24%). Participants who reported smok-
ing at both 3 and 12 months had a high proportion of anxiety/depression problems at baseline
(36%) and at the two follow-ups (42% and 36% respectively).
Discussion
In the current study, the mean EQ-5D utility score was 0.8252 (SD 0.2594) at baseline and
0.8072 (SD 0.2456) at 12 months, which is similar to the score reported for a representative
sample of English former smokers, 0.8225 (SD 0.2512) [2]. It was found that EQ-5D utility at
baseline was negatively associated with certain participant characteristics, including older age,
being female, unemployed, and heavy smoking before quitting. At follow-up, those who had
relapsed had a lower quality of life, while those maintaining abstinence had a small and non-
significant increase in HRQoL. The difference in HRQoL between the relapsers and continu-
ous quitters at follow-up was statistically significant, and due to changes in anxiety or depres-
sion, with no evidence of changes in other EQ-5D dimensions.
A study of the English general population found that heavy smokers had poorer HRQoL in
all five EQ-5D dimensions compared with never smokers [2]. In the current study of short-
term quitters, analyses of EQ-5D dimensions revealed that the differences in HRQoL between
relapsers and continuous quitters were mainly attributable to problems in the anxiety/depres-
sion dimension. This finding was consistent with those from a previous study that examined
the relationship between smoking cessation and HRQoL using the EQ-5D [20]. The associa-
tion between anxiety/depression and smoking or smoking cessation is complex, and results
from different studies are often inconsistent. For example, a recent study did not find a long-
Table 3. Results of logistic regression analyses of associations between anxiety or depression problems and smok-
ing status at baseline, 3 and 12 months.
Any anxiety/depression problems Odds ratio (95% confidence interval); P value
Smoking at 3 months Smoking at 12 months
At baseline 1.27 (0.95–1.70); P = 0.112 1.03 (0.80–1.31); P = 0.841
At 3 months 2.28 (1.63–3.17); P<0.001 1.13 (0.87–1.47); P = 0.354
At 12 months 1.22 (0.87–1.71); P = 0.246 1.49 (1.14–1.95); P = 0.003
Logistic regression analysis using smoking at 3 or 12 months as the dependent variable, and adjusted for age, sex,
married or not, unemployment, low education (GCSE or lower), receipt with free prescription, and the first cigarette
in 5 minutes after waking up.
https://doi.org/10.1371/journal.pone.0205992.t003
Smoking relapse and quality of life
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term impact of smoking cessation on depression, although depression reduced possibility of
quitting [21]. Because smokers often use cigarettes to attempt to cope with stress and anxiety,
many smokers and some health professionals mistakenly believe that smoking cessation will
worsen stress and anxiety symptoms [22]. This belief may arise because tobacco withdrawal
symptoms include anxiety and depression immediately after abstinence, although withdrawal
symptoms last only a few weeks [23]. However, many previous studies found that failed quit
attempts may increase anxiety or depression [7–9, 24, 25], and successful smoking cessation
reduces stress and anxiety [4–6, 22].
A prospective study published in 1990 examined the relation between changes in stress lev-
els and changes in smoking status, and concluded that the relation was possibly bidirectional
[5]. Although the association between changes in smoking status and changes in stress levels
was consistently observed in other studies [22, 26], the causal direction remains uncertain. In a
Fig 2. Proportions of people with anxiety/depression problems by any smoking during the 7-days before the
3-month and 12-month follow-up.
https://doi.org/10.1371/journal.pone.0205992.g002
Smoking relapse and quality of life
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recent study by Taylor and colleagues [13], deterioration in mental health after achieving and
maintaining abstinence until four months did not predict relapse to smoking by 12 months. In
the current study, we found that smoking relapse was accompanied with increased anxiety or
depression problems measured at the same time. However, anxiety or depression problems at
baseline or at 3 months were not associated with smoking relapse at 12 months (Table 3, Fig
2). It is also interesting to note that relapse to smoking by 3 months was associated with an
increase in anxiety and depression at that time, while returning to abstinence by 12 months
was associated with reduced anxiety and depression at 12 months (Fig 2).
The effects of anxiety or depression on smoking relapse may occur promptly with little
delay, so that smoking is closely associated with the present, rather than the previous, mental
status. This may explain why deterioration in mental health did not predict smoking relapse
after eight months in a previous study [13]. However, as a failed quit attempt, relapse to smok-
ing itself is likely a stressful incident. In contrast to the immediate effects of anxiety and
depression on smoking relapse, the beneficial effects of smoking cessation on anxiety or
depression may not be perceived immediately and may often be complicated by withdrawal
symptoms. Consequently, people with mental illness have a higher smoking prevalence and
are less likely to quit than people without mental illness [27]. Although accumulating evidence
suggests that smoking cessation improves mental health and reduces stress or depression in
long term, more efforts are required to manage stress and other depressive symptoms in smok-
ing cessation interventions, whilst emphasising these potential longer mental health benefits.
Strengths and limitations
This is the first study to examine changes in EQ-5D based HRQoL in a large number of people
who had quit smoking for several weeks after receiving smoking cessation treatment. The
study provided data on EQ-5D based utility scores by smoking relapse status, which will help
evaluations of long-term cost-effectiveness and cost-utility of smoking cessation and tobacco
control interventions [28]. By measuring EQ-5D status at baseline, 3 and 12 months, and col-
lecting data on smoking status at 3 and 12 months, we were able to investigate the association
between changes in smoking status and changes in HRQoL (specifically, changes in anxiety/
depression problems).
We found that the difference in changes in HRQoL between relapsers and continuous quit-
ters was statistically significant, although the clinical and public health importance of the dif-
ference was unclear. We focused on the association between smoking relapse and HRQoL in
the present study. However, it should be stressed that smoking relapse is also associated with
other demographic or socioeconomic factors, including age, marital status, employment status,
and living with a partner who smokes [14]. The participants of the current study were predom-
inantly white (98%), reflecting the ethnic composition of the area; pregnant women, people
younger than 18 years and those who were unable to read English were excluded [14], so that
the results of the current study may not be generalizable to these groups. As mood and smok-
ing status were assessed infrequently, this study alone cannot clarify the causal pathway. The
current study was observational in nature, and we could not rule out the existence of other fac-
tors or events that were associated with both relapse to smoking and changes in EQ-5D
responses.
Conclusions
Relapse to smoking is associated with reduced quality of life measured by EQ-5D, which seems
mainly attributable to problems of anxiety and/or depression. Further research is required to
more fully understand the relationship between smoking and health-related quality of life, and
Smoking relapse and quality of life
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to develop cessation interventions by taking into account the impact of anxiety and depression
on smoking.
Supporting information
S1 Dataset. Data from the SHARPISH trial for smoking relapse and health-related quality
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